Reboxetine Patent Application for Narcolepsy and Cataplexy Treatment
Summary
USPTO published patent application US20260097040A1 by Herriot Tabuteau covering methods of treating narcolepsy with cataplexy using reboxetine or esreboxetine. The application includes pharmaceutical compositions and instructions for use in treating the condition. Filing date was December 11, 2025, with publication on April 9, 2026.
What changed
USPTO published patent application US20260097040A1 disclosing methods of treating narcolepsy with cataplexy by administering reboxetine or esreboxetine to a patient. The application covers pharmaceutical compositions containing reboxetine and kits with instructions for use in treating the condition. Invented by Herriot Tabuteau.
Pharmaceutical companies and drug developers should monitor this application as it may affect freedom-to-operate considerations for reboxetine-based therapies targeting narcolepsy and cataplexy. Parties developing similar norepinephrine reuptake inhibitors for sleep disorders may need to evaluate potential patent conflicts.
What to do next
- Monitor for updates
Archived snapshot
Apr 12, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
USE OF REBOXETINE TO TREAT NARCOLEPSY
Application US20260097040A1 Kind: A1 Apr 09, 2026
Inventors
Herriot Tabuteau
Abstract
Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine (including esreboxetine) to a human being in need thereof. Reboxetine (including esreboxetine) may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine (including esreboxetine) and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being.
CPC Classifications
A61K 31/5375 A61P 25/20
Filing Date
2025-12-11
Application No.
19417205
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.